Here, we provide a comprehensive study related to the risks of all biopharmaceutical firms going public in the USA between 1996 and 2015. We found 355 firms that met our requirements for being in the sector that focuses on creating drugs for humans. Collectively, these firms spent approximately US$86.9 billion on research and development (R&D) during this time. They also lost approximately US$69.3 billion in combined net income. We also examine the delisting of these firms from a public market, their number of collaborators at the initial public offering (IPO), and estimate the percentage ownership by other biopharmaceutical firms at the IPO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2018.06.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Next-generation vaccines for influenza B virus: advancements and challenges.
Arch Virol
January 2025
CAS Key Laboratory of Molecular Virology & Immunology, Institutional Center for Shared Technologies and Facilities, Pathogen Discovery and Big Data Platform, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Yueyang Road 320, Shanghai, 200031, China.
To battle seasonal outbreaks of influenza B virus infection, which continue to pose a major threat to world health, new and improved vaccines are urgently needed. In this article, we discuss the current state of next-generation influenza B vaccine development, including both advancements and challenges. This review covers the shortcomings of existing influenza vaccines and stresses the need for more-effective and broadly protective vaccines and more-easily scalable manufacturing processes.
View Article and Find Full Text PDFImpact of accelerated review policy on portfolio planning of vaccine companies.
Front Public Health
December 2024
School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China.
Background: With the introduction of the accelerated drug review policy in China, the clinical research and development time and the review and approval time of drugs have been shortened accordingly. Especially under the influence of the COVID-19 pandemic, the vaccine formulations released through the accelerated review policy are springing up, and the question of how the accelerated review policy affects the investment portfolio of vaccine enterprises has also attracted more and more attention.
Aims And Methods: The article uses mixed-integer linear programming to develop a new model on portfolio planning for vaccine companies based on the accelerated review policy context.
Antibodies to watch in 2025.
MAbs
December 2025
Business Intelligence Research, The Antibody Society, Inc., Framingham, MA, USA.
The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025.
View Article and Find Full Text PDFDuration of Ice Hockey Play and Chronic Traumatic Encephalopathy.
JAMA Netw Open
December 2024
Boston University Alzheimer's Disease Research Center, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts.
Importance: Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impacts (RHIs). Prior research suggests a dose-response association between American football play duration and CTE risk and severity, but this association has not been studied for ice hockey.
Objective: To investigate associations of duration of ice hockey play with CTE diagnosis and severity, functional status, and dementia.
Does the impact of open innovation depend on contextual factors? A case of the Korean biopharmaceutical industry.
PLoS One
November 2024
Graduate School of Public Health and Healthcare Management/Catholic Institute for Public Health and Healthcare Management, Songeui Medical Campus, The Catholic University of Korea, Seoul, Korea.
Article Synopsis
- - Investments in the biopharmaceutical industry are rising globally, and the importance of original technology and intellectual property rights is crucial due to the industry's technology-intensive nature.
- - Open innovation (OI) is becoming more relevant in this sector because of high R&D costs and long development timelines, although research on how contextual factors impact the relationship between OI and innovation performance is limited, especially in developing countries.
- - A study focusing on South Korean biopharmaceutical firms examined how factors like government R&D support, absorptive capacity, and alliance management capacity affect OI's impact on patent performance, finding that technological cooperation has a positive effect on patents, enhanced by strong government support and absorptive capacity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!